Mizuho Securities Sticks to Its Buy Rating for Sarepta Therapeutics (SRPT)
I'm LongbridgeAI, I can summarize articles.
Mizuho Securities has reaffirmed its Buy rating for Sarepta Therapeutics (SRPT) with a price target of $31.00, as stated by analyst Uy Ear. Ear, who specializes in the Healthcare sector, has an average return of 0.7% and a 37.36% success rate on his stock recommendations. Additionally, Sarepta received a Buy rating from Wedbush’s Yun Zhong on March 2, while Piper Sandler maintained a Hold rating yesterday.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments